Enanta Pharmaceuticals Inc (ENTA) Options

The wait is frustrating for sure. Especially now that the general market seems to have bottomed

You hope.

They need to show the street that they can close a deal and hopefully soon.

The wait is frustrating for sure. Especially now that the general market seems to have bottomed

Could be one news away from big gain

Pathetic stock performance and the company is requesting more incentive options be granted ?? The current management doesn’t deserve anymore in my opinion until they right this ship.

Baby FLO just up-chucked.........................

Just brutal. 

Vaccines are the new tobacco....

Only to the clueless.

Vaccines are the new tobacco....

Yeah, bumpy ride indeed, it should be worthwhile at the end.

And I don’t want to get off the ride and see a partnership or buyout news showing up right after

So I hold

Crazy swing over… I hope so. ENTA has been one bumpy ride. 🍀🍀🍀🍀

The volume is so low today
Less than 60k and only 1.5 hrs become close.

Maybe the crazy swing will be behind us soon, I hope

Some have likely reshorted the stock by now.

ENTA needs to execute and finalize an RSV or even an immunology deal. A major factor contributing to the negative asset value is the market’s lack of confidence in management’s execution.

On a POSITIVE note -

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significant Decline in Short Interest

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was the target of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 2,600,000 shares, a drop of 27.2% from the February 13th total of 3,570,000 shares. Based on an average trading volume of 562,300 shares, the short-interest ratio is presently 4.6 days. Approximately 13.1% of the company's shares are short sold.

https://www.marketbeat.com/instant-alerts/short-interest-in-enanta-pharmaceuticals-inc-nasdaqenta-decreases-by-272-2025-03-16/

Shorts appear to be back at it. Not one to often allege market manipulation but the pre-market action is unusually strange. Down $0.50 - it’s not a lot of shares but can see how some would be influenced. Hopefully we put in a solid bottom sooner than later.

the appropriate way to deal with that problem is to take corporate actions that raise the share price!

I agree.
But I can feel their pain too

At minimum, the stock should trade mid-teen, not single digit

The vote against was 26%, which is not out of line for these kinds of proposals. I voted my own shares against the proposal because I don't think management has earned the right to create any additional dilution beyond the shares already allocated to the Equity Plan. ENTA tried to justify the additional shares by noting that all stock options are underwater, but I think the appropriate way to deal with that problem is to take corporate actions that raise the share price!

In any event, I'm pretty confident in stating that the vote on the Equity Plan proposal was not a material factor in today's selloff.

Maybe someone is not pleased with the additional shares then. The Vote Against seems significant

Annual-meeting proposal to allocate an additional 800K shares to the 2019 Equity Incentive Plan passed:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001177648/000095017025040230/enta-20250313.htm

Added more. I remember feeling i should have added more when it ran to 7 then 8.7

I guess now it’s my chance ;)

For sure, buyout is my blue sky case too

But how would participating in an immunology conference translate to no buyout or even a delay on potential buyout?

Even if they are talking to someone about a buyout, they wouldn’t stop going to conferences unless they are really really close?

And I think the fact that the insider buy just happened recently - it should be well known we are not there yet

Sellers will regret big time when the deal is announced.

For now, I regret didn’t sell when shares are 40 percent higher few days ago

Agree but buyout potential is always part of the equation and if you move that probability down the stock can react. I could be totally wrong of course. I personally am ok w a reset based on how hot these preclinical assets are based in recent deal making and the number of early stage companies that have gotten funded in the space. I’ll take a buyout too! Still think RSV assets look very appealing

It would be silly if that’s the reason for the selloff as it should be well telegraphed by now they are going to be focus on immunology

Brutal. Investors despise it when companies do a do-over..

Yes
THRD data probably gives them some opening to differentiate only BPMC is ahead in the oral kit space w a clean molecule so far
My guess on sell off is less perception a buyout could be happening as they promote immunology

Sell off? Who knows. Management… secure deal / partner for the RSV assets and build shareholder value pls.

What’s up with the sell off?

Nice, i believe this is the first time ever they present in immunology focus conference.

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Mar 17, 2025

WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 17, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-present-hc-wainwright-3rd-annual

They skipped almost all investor conferences this year except for one. At least they're participating in a medical conference.

Thanks Flo..

March 14 POSTERS Presentations:

A. EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSVRSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_EDP323-PKPD-Poster_KElmore-3.14.25.pdf

B. In Vitro Characterization of Respiratory Syncytial Virus Inhibitors RSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_InVitro-Characterization_MRhodin-3.14.25.pdf

C. A Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young ChildrenRSV: Zelicapavir - Poster

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_Phase2-Zelicapavir-Poster_SHuang-3.14.25.pdf

D. First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV Results from a Phase 2a Human Viral Challenge Study RSV: EDP-323 -Presentation

https://www.enanta.com/wp-content/uploads/2025/03/RSV2025_EDP323-Oral-Pres_JDevincenzo-3.14.25.pdf

There will be an 8-K filing soon to announce the voting. The only issue of consequence is the company's proposal to allocate about 1M additional shares to the 2019 Equity Incentive Plan.

Anyone attending the AGM?

Any notes would be appreciated

Got accepted for an oral and a late breaker....not bad

Mar 12, 2025 
PDF VersionWATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 12, 2025-- Enanta Pharmaceuticals, Inc.(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13thInternational RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil.Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation. Data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for the treatment of RSV in young children will be presented in a late breaker poster. An additional poster will highlight distinctions among fusion, N, and L inhibitors with respect to preclinical antiviral effect and resistance profiles, while a third poster will detail PK and PK/PD results from the EDP-323 Phase 2 human challenge study.Oral Presentation:
Date: Friday, March 14, 2025
Time: 12:00 – 12:15 PM Brasília Time (BRT)/11:00 – 11:15 AM Eastern Daylight Time (EDT)
Session Name: RSV Monoclonal Antibodies and Antivirals
Abstract ID: ARBI0162
Title: “EDP-323, a First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV: Results from a Phase 2a Human Viral Challenge Study”
Location: Bourbon Cataratas do Iguazu, Bourbon Ballroom
Presenter Name: John P. DeVincenzo, M.D.Late Breaker Poster Presentation:
Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Session Name: RSV Monoclonal Antibodies and Antivirals
Abstract ID: ARBI0332
Poster Number: 253
Title: “A Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young Children”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: John P. DeVincenzo, M.D.Poster Presentations:
Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Abstract ID: ARBI0249
Poster Number: 161
Title: “In Vitro Characterization of Respiratory Syncytial Virus Inhibitors”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: Michael Rhodin, Ph.D.Date: Friday, March 14, 2025
Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT
Abstract ID: ARBI0158
Poster Number: 153
Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV”
Location: Bourbon Cataratas do Iguazu, Pavilion C
Presenter: Kimberly Elmore (Mills), PharmD

PFE is only one of many possible suitors - lots of folks have an ID presence, and immunology is hot
The company has done nothing since partnering in HCV so I understand the skepticism of some, but obviously I am firmly in the camp that there will be some sort of positive development near term (my near term includes waiting for the HR data which hopefully will still come in by the end of the year)

I guess by now, they have talked to all potential partners so really, they can't really do much about it...
Maybe someone will knock their door for it some days.. $PFE should just buy us out really, for the nth time.

I guess it is not dead dead, but it is not part of the business development goals for the year in the latest corporate presentation, so I think it is fair to say it is *mostly dead*

*Miracle max?

so I guess 235 is not completely dead dead, right?
Seems there is a pathway as long as you have money to throw at it?

I didn't realize GILD is looking at an oral prodrug of Remdesivir for RSV - looks like it is in phase 2 for HR adults and pediatrics
MOA seems to be much like lumicitabine that was dropped by JNJ due to preclinical tox, but it also had limited efficacy - nuke targeting the L protein
another competitor, but clearly there is still an appetite for an RSV antiviral among large pharma

Is there a market for new COVID-19 drugs?
Waning interest in the virus has drugmakers trying for new angle - March 10

Three antivirals are available in the US today: Pfizer’s Paxlovid, or nirmatrelvir with ritonavir; Gilead Sciences’ Veklury, or remdesivir; and Merck & Co.’s Lagevrio, or molnupiravir. All come with their own drawbacks. Paxlovid interacts negatively with a slew of common medications for diseases like arrhythmia and migraine, making it difficult for people with those conditions—many of whom are at a higher risk for COVID-19 complications precisely because of those conditions—to take it. Veklury has to be administered intravenously, and Lagevrio isn’t as effective as Paxlovid is, making it a last line of treatment.

Enanta CEO Jay Luly is hopeful that it’ll soon become clear to potential partners that EDP-235 has a market, in part because of these drawbacks.

“We firmly believe there is a need for a conveniently-dosed, safe and effective once-daily oral treatment with fewer drug-drug interactions (DDI) and an improved tolerability profile (doesn’t taste bad),” Luly says by email. “There is a very low uptake of boosters, leaving most of the population vulnerable to infection. The ultimate market for COVID treatments remains to be determined, but an improved antiviral with less DDI complications and better tolerability would certainly broaden the current multi-billion-dollar market.”

https://cen.acs.org/pharmaceuticals/market-new-COVID-19-drugs/103/i6

I added some shares today, FWIW.

We will see. Would be a very different company a year out.

I don't think they are going to shake up management at least through phase 1 of the kit inhibitor
once they get into POC they are going to want experts in those disease areas, and if RSV is totally partnered out I would think rotate those folks out

If they partner both then they may as well sell the company

Maybe the plan is to sell it actually, as if the plan is to run the immology further, we should expect a CEO succession plan soon, right?

I think that is their plan. If they partner both then they may as well sell the company

Will there be PR on $30M tax refund?

I wish ENTA can partner out RSV soon and keep the immology programme in house as long as possible. The upside will be quite unimaginable if they have some success there.

THRD is looking to partner up* but I’m not sure that is a good proxy for value of the kit drug bc their healthy volunteer data was a bit murky. *they announced a workforce reduction and are exploring “strategic options”
The LFT abnormality in the highest dose arm was of greater magnitude than the 2 placebo elevations. They also had more hematological toxicity than expected, especially at the highest dose level (where they did get to 80 percent reduction in mean tryptase). So they might be more limited in dosing moving forward.

https://ir.thirdharmonicbio.com/static-files/1ef636b6-3f8f-4c48-b0f8-0b4595844526

BPMC had a recent poster with their phase 1 data which seemed cleaner.

https://www.blueprintmedicines.com/wp-content/uploads/2025/03/Blueprint-Medicines-AAAAI-WAO-2025-BLU-808-Wild-Type-KIT-Safety-PK-Healthy-Volunteers-Poster.

Interesting to see addtional partnership around $ENTA's new focus area. One day, it will be with $ENTA I hope.
Or, $PFE just buy us out.